News
Important Only
Snow Lake Resources gains on Trump order to boost US critical minerals production
** Uranium miner Snow Lake Resources' LITM.O shares up 18.5% to $0.71** U.S. President Donald Trump on Thursday invoked emergency powers to boost domestic production of critical minerals used widely across the economy as part of a broad effort to offset China's near-total control of the sect...Reuters
Fri, Mar 21
TOT BIOPHARM (1875.HK) Turns a Profit for the First Time, Reports 2024 Net Income of RMB 34.8M
Guru Club, March 12丨TOT BIOPHARM - B (1875.HK) announced that for the full-year results ending December 31, 2024, the Company reported better-than-expected performance, with annual revenue reaching RMB 1.098 billion, representing a 41% year-on-year increase. In 2024, it achieved a turnaround from loss to profit for the first time, posting a net profit of RMB 34.8 million. With continuously enhanced cash generating capabilities, the net cash from operating activities has been positive for three consecutive years, reaching RMB116.4 million in 2024. The CDMO (Contract Development and Manufacturing Organization) business demonstrated robust growth potential with a notable funnel effect. Leveraging its cutting-edge technology platforms to enhance front-end pipeline promotion, the Company saw a significant increase in early-stage projects. It added 58 new projects throughout the year, including 48 ADC (Antibody - Drug Conjugate) projects, bringing the total to 153 projects. Notably, it secured 2 pre-BLA (Pre-Biologics License Application) projects, bringing the total number to 8, fully demonstrating the Company's outstanding capability in late-stage CDMO commercialization projects and further strengthening its potential for future revenue expectations. The Company's service backlog on hand reached RMB 191 million, marking a 39% year-on-year growth.Widely recognized by the industry world-wide, the Company's high-standard quality management system has passed many production site inspections by relevant drug regulatory authorities and GMP compliance inspections in many countries, as well as several GMP inspections by customers and third-party consulting agencies. In 2024 alone, the Company received 38 GMP audits in total, including 7 official GMP audits (3 by foreign authorities and 4 by domestic authorities) and 2 EU QP audits (one of which was passed with zero defects). The Company also obtained GMP certificates from countries such as Colombia, Egypt, and Indonesia. Additionally, the Company obtained the Accreditation of Foreign Manufacturers by the PMDA in Japan, signifying that TOT BIOPHARM's production lines and quality system comply with Japanese pharmaceutical quality and safety standards. Furthermore, the Company assisted its customers in completing inspections by their overseas partnering multinational pharmaceutical companies and other institutions on multiple occasions, and successfully collaborated with its customers in completing the licensing with high recognition.21/03/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Fri, Mar 21
TOT BIOPHARM (1875.HK) Turns a Profit for the First Time, Reports 2024 Net Income of RMB 34.8M
Guru Club, March 12丨TOT BIOPHARM - B (1875.HK) announced that for the full-year results ending December 31, 2024, the Company reported better-than-expected performance, with annual revenue reaching RMB 1.098 billion, representing a 41% year-on-year increase. In 2024, it achieved a turnaround from loss to profit for the first time, posting a net profit of RMB 34.8 million. With continuously enhanced cash generating capabilities, the net cash from operating activities has been positive for three consecutive years, reaching RMB116.4 million in 2024. The CDMO (Contract Development and Manufacturing Organization) business demonstrated robust growth potential with a notable funnel effect. Leveraging its cutting-edge technology platforms to enhance front-end pipeline promotion, the Company saw a significant increase in early-stage projects. It added 58 new projects throughout the year, including 48 ADC (Antibody - Drug Conjugate) projects, bringing the total to 153 projects. Notably, it secured 2 pre-BLA (Pre-Biologics License Application) projects, bringing the total number to 8, fully demonstrating the Company's outstanding capability in late-stage CDMO commercialization projects and further strengthening its potential for future revenue expectations. The Company's service backlog on hand reached RMB 191 million, marking a 39% year-on-year growth.Widely recognized by the industry world-wide, the Company's high-standard quality management system has passed many production site inspections by relevant drug regulatory authorities and GMP compliance inspections in many countries, as well as several GMP inspections by customers and third-party consulting agencies. In 2024 alone, the Company received 38 GMP audits in total, including 7 official GMP audits (3 by foreign authorities and 4 by domestic authorities) and 2 EU QP audits (one of which was passed with zero defects). The Company also obtained GMP certificates from countries such as Colombia, Egypt, and Indonesia. Additionally, the Company obtained the Accreditation of Foreign Manufacturers by the PMDA in Japan, signifying that TOT BIOPHARM's production lines and quality system comply with Japanese pharmaceutical quality and safety standards. Furthermore, the Company assisted its customers in completing inspections by their overseas partnering multinational pharmaceutical companies and other institutions on multiple occasions, and successfully collaborated with its customers in completing the licensing with high recognition.21/03/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Fri, Mar 21
3 Reasons to Buy NuScale Power Stock Like There's No Tomorrow
NuScale Power (NYSE: SMR) is not an investment for the faint of heart. Indeed, it is losing money today and will probably continue to do so for at least another few years. But if you can handle a little risk, this nuclear power start-up is extremely attractive.Here are three of the primary reasons w...The Motley Fool
Fri, Mar 21
The Emotional Evolution of the Intelligent Era: Tuya Smart and DeepSeek Lead the Future of AI-driven Companionship
NEW YORK, March 21, 2025 /PRNewswire/ -- Tuya Smart (NYSE: TUYA, HKEX: 2391), a global AI cloud platform service provider, is redefining the role of AI in the smart home ecosystem, turning cold technology into an emotionally intelligent companion. Imagine returning home after a long day, your mind ...PR Newswire
Fri, Mar 21
US airlines' shares fall after Heathrow Airport closure
** Shares of U.S. airlines fall in early trading after Britain's Heathrow Airport was shut, sparking global travel turmoil** Heathrow Airport closes after huge fire knocked out power, stranding passengers around the world and forcing flight cancellations and diversions ** Delta Air Lines DAL.N ...Reuters
Fri, Mar 21
Is Lucid Group Stock a Buy Now?
Lucid Group (NASDAQ: LCID) is a premium electric vehicle (EV) manufacturer that has captured attention with its innovative automotive offerings. The company has made noteworthy advancements in EV technology, especially with the Lucid Air and the upcoming Lucid Gravity SUV.Lucid's long-term growth po...The Motley Fool
Fri, Mar 21
Micron falls on conservative gross margin forecast
** Micron Technology shares MU.O fall 7.8% to $94.88** The memory chips maker forecast Q3 gross marigns of 36.5% vs analysts' estimates of 36.9% - LSEG data** The outlook is probably viewed with some disappointment, said Brian Chin, analyst at Equity Research** Citi says, "Gross margins coul...Reuters
Fri, Mar 21
SMCI stock upgraded to Neutral at JPMorgan after ‘cycling past’ filing challenges
Investing.com -- Super Micro Computer (NASDAQ:SMCI) stock received an upgrade at JPMorgan (NYSE:JPM), to Neutral from Underweight, after the AI server maker “has cycled past the uncertainty” related tInvesting.com
Fri, Mar 21
UK's Oxford Nanopore gains as CEO reportedly flags takeover exposure
** Biotech group Oxford Nanopore Technologies ONT.L up as much as 5.7% at 115.9p ** Gene sequencing specialist is now "exposed" to acquisition, CEO and co-founder Gordon Sanghera told FT** ONT's shares have lost 85% since its peak in 2021** "Bankers have said it could be attractive t...Reuters
Fri, Mar 21
Did Nike Just Have Its Worst Quarter Ever?
In this video, I will review Nike's (NYSE: NKE) latest earnings report and management comments about the company's future. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of March 20, 2025. The video was p...The Motley Fool
Fri, Mar 21
CANADA STOCKS-TSX opens lower as tariff worries persist
March 21 (Reuters) - Canada's main stock index opened lower on Friday, led by falling mining stocks, on worries over implications of trade tariffs on economic growth even as the index was set for a weekly advance.At 9:31 a.m. ET (1331 GMT), the Toronto Stock Exchange's S&P/TSX composite ...Reuters
Fri, Mar 21
US STOCKS SNAPSHOT-Wall St opens lower on tariff woes; FedEx falls on bleak forecast
March 21 (Reuters) - Wall Street opened lower on Friday as investors continued to navigate the complex landscape of tariffs, with FedEx becoming the latest firm to adjust its annual projections due to economic uncertainties.At 09:30 a.m. ET, the Dow Jones Industrial Average .DJI fell 324.31 points, ...Reuters
Fri, Mar 21
Biofrontera Inc reports results for the quarter ended December 31 - Earnings Summary
Biofrontera Inc BFRI.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.80. The mean expectation of two analysts for the quarter was for a loss of 2 cents per share. Wall Stree...Reuters
Fri, Mar 21
F&G Annuities & Life slumps as $280 mln stock offering priced
** F&G Annuities & Life Inc's FG.N shares down 5.3% premarket to $34.50, over 16-mth low, after equity raise ** Des Moines, Iowa-based insurer late Thurs announced pricing of 8 mln shares at $35 for gross raise of $280 mln ** Offering price represents 4% discount to stock's...Reuters
Fri, Mar 21
1 Wall Street Analyst Thinks Tesla Will Hit $425. Is it a Buy Around $235?
Tesla (NASDAQ: TSLA) has long been a battleground stock, but recently, the fight between bulls and bears around the EV maker has reached a fever pitch.Shares of Tesla essentially doubled following the election, but they have given back all of those gains since the inauguration as controversy continu...The Motley Fool
Fri, Mar 21
U.S. STOCKS ON THE MOVE-Microchip Technology, IAC, Micron Technology
The Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/3dKUyB8Wall Street was set to open lower on Friday as investors continued to navigate the complex landscape of tariffs, with FedEx becoming the latest firm to adjust its annual projections due to e...Reuters
Fri, Mar 21
Is Camden Property Trust a Stock to Buy and Hold Forever? Here's Why It Could Be.
Camden Property Trust (NYSE: CPT) is a real estate investment trust, or REIT, that specializes in multifamily properties. Its core property type is apartment communities in or near major U.S. cities. Including properties currently under construction, the company owns about 60,800 apartment homes in ...The Motley Fool
Fri, Mar 21
